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Abstract
Background: Current guidelines recommend parvovirus revaccination of adult dogs no more frequently than every
3 years. The aim of this study was to determine the prevalence of dogs showing protective serum antibody titres
against canine parvovirus 2 in breeding kennels in Northern Italy and to assess the effect of time from vaccination
and the sex of the dog on antibody titres. The study was carried out on 370 animals of different breeds kept in 33
breeding kennels. Antibodies to canine parvovirus 2 in serum samples were measured with an indirect
immunoenzymatic assay validated by the manufacturer in relation to the ‘gold standard’ haemagglutination
inhibition test. The number of months that had elapsed since the last vaccination was calculated for each animal
and categorized into the following classes: < 12 months; 13–24 months; 25–36 months; 37–48 months; and > 49
months.
Results: The prevalence of ‘unprotected’ dogs was 4.6%. A satisfactory solid herd immunity was present in the
majority of breeding kennels, although some vaccination failures were detected. A significant negative correlation
was found between antibody titre and months since last vaccination. Comparable antibody titres were found in the
first 3 years after vaccination. Although the antibody titre over time was not affected by the sex of the dog,
‘unprotected’ females had been vaccinated more recently than males with analogous low titres.
Conclusions: Parvovirus revaccination of adult dogs every 3 years, as currently recommended, is also the
appropriate recommendation for breeding kennels. Serological tests could be a useful tool to assess the
effectiveness of vaccination.
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Background
Canine parvovirus type 2 (CPV-2) is the aetiological agent
of a severe viral disease in dogs. It emerged as a dog
pathogen in the late 1970s, when outbreaks of haemor-
rhagic gastroenteritis were observed in puppies and young
dogs in kennels and shelters worldwide [1]. Moreover, the
virus was demonstrated to be responsible for myocarditis
in puppies [2]. CPV-2 is a nonenveloped single-stranded
DNA virus that is closely related to feline parvovirus
(FPV) but exhibits more rapid evolution [3]. Many anti-
genic variants (CPV-2a, CPV-2b and CPV-2c) have indeed
completely replaced the original type-2 [3, 4]. Contagion
occurs through the oronasal route, and the incubation
period is three to 7 days [3]. CPV-2 can survive in the en-
vironment for more than a year, allowing the exposure of
susceptible dogs to infected materials such as faeces, vom-
itus, or fomites. Virus shedding starts a few days prior to
the occurrence of clinical signs, progressively declining 3–
4 weeks postexposure [5].
Vaccination is the main method for controlling the dis-
ease, and modified live virus (MLV) vaccines are used to ob-
tain long-term immunity. Maternally derived antibodies
acquired via colostrum protect newborns during the first
weeks of life and can interfere with vaccination [4]. Lifelong
immunity to the diseases develops after natural CPV-2
infection/disease, while the persistence of antibodies in
MLV-vaccinated dogs can last up to 10 years [6]. Current
guidelinesrecommend parvovirus revaccination of adult
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dogs no more frequently than every 3 years [7] since the
minimum duration of immunity after MLV vaccination may
be even longer.
The aim of this study was to determine the prevalence
of dogs with protective serum antibody titres against
CPV-2 in medium-sized breeding kennels in Piedmont,
Northern Italy and to investigate the effect of time from
vaccination and the sex of the dog on antibody titres.
Results
Four dogs, three females and a male, had never been
vaccinated: three of them (age 11, 14 and 16 years),
housed in the same kennel, had a titre lower than the
cut-off titre (approximately 1:65), while the fourth dog
(age 2 years), kept in a different kennel, had a titre of 1:
184, which is deemed protective.
In vaccinated animals, a significant negative correl-
ation was found between antibody titre and the number
of months since the last vaccination (Spearman r = −
0.2048; P < 0.0001) (Fig. 1). Time significantly affected
the antibody titre (P < 0.0001), with comparable values
in the first 3 years after vaccination (Fig. 2). Although
the mean antibody titre was still protective even 49
months after the last vaccination, there was very large
individual variation, and the median values dropped after
the third year (Table 1); analogously, the percentage of
unprotected animals was 2.7, 6.1 and 3.4 in the first 3
years and became 10.5 and 11.1 in the last two time cat-
egories, between 37 and 48 months and more than 49
months since the last vaccination, respectively.
Although the antibody titre over time was not affected
by the sex of the dog, females with a titre lower than 1:
100 tended to be vaccinated more recently than males
with analogous low titres (P = 0.0509) (Fig. 3).
In the 17 dogs in which the antibody titre was lower
than 1:100, a longer period of time had elapsed since the
last vaccination (P = 0.0126) in comparison to the “pro-
tected animals” (Fig. 4). The prevalence of ‘unprotected’
dogs was 4.6%, which was not significantly different be-
tween males (5.4%) and females (4.3%). Eight ‘unprotected’
dogs were older animals that had been vaccinated more
than 3 years earlier; however, four young dogs, approxi-
mately 1 year of age, showed lower than the cut-off anti-
body titre, although they had been vaccinated less than 1
year earlier. A four-year-old German Shepherd, annually
revaccinated, had an antibody titre lower than 1:100 2
months after the last vaccination. In the list of ‘unpro-
tected’ dogs, two breeding kennels were represented with
two and three dogs, respectively.
Discussion
Canine parvovirus is highly feared in breeding kennels be-
cause the disease that it induces causes high morbidity and
often mortality in puppies and young dogs. In addition to
severe haemorrhagic gastroenteritis, puppies less than 3
months of age develop myocarditis, and CPV-2 myocardial
Fig. 1 Correlation between antibody titre and the number of
months since last vaccination (r = − 0.2048; P < 0.0001). An arbitrary
value of 25,000 was attributed to out-of-scale antibody titres
Fig. 2 Comparison of antibody titres among different categories of
time elapsed since last vaccination (Categories: < 12 months; 13–24
months; 25–36 months; 37–48months; and > 49months). (* = P <
0.05; ** = P < 0.01; and *** = P < 0.001)
Table 1 Serological titres of dogs in the five periods of time
(months) since last vaccination (mean ± standard deviation and
minimum, median, and maximum values) (N = number of
animals for each time category)
Months N Antibody titre
Mean ± SD Minimum Median Maximum
< 12 224 6009 ± 7589 61.4 2578 25,000
13 < x < 24 66 5071 ± 6906 65.7 2346 25,000
25 < x < 36 29 4485 ± 6653 80.9 1682 25,000
37 < x < 48 19 2279 ± 5667 61.8 334.1 25,000
> 49 27 2082 ± 4876 59.5 439.4 25,000
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infection is likely an underrecognized cause of cardiac dam-
age in young dogs [8]. Collectively housed dogs can have a
higher risk of parvovirus infection, depending on many var-
iables such as population immunization, population density,
sanitation of facilities, isolation protocols for new dogs, and
turn-over rates. The virus is resistant to most disinfectants
and is not easily removed from a contaminated environ-
ment, especially when organic material is present, or from
soil and grass [9, 10].
Good hygienic practices in the kennels, including disin-
fection of all exposed surfaces and personnel, are primary
control measures, given the ability of the virus to survive
for a long time in the environment. Sodium hypochlorite
represents an effective viricidal reagent, provided that con-
tact time is at least 10min [11].
CPV-2 antibody titres can be used to assess whether in-
dividual dogs are protected against infection: neutralizing
antibody titres for CPV-2 are indeed recognized correlates
of protection, so seropositive dogs above the cut-off value
are deemed protected against infection [7].
A substantial proportion of dogs in the present study
had protective antibody titres, so satisfactory solid herd
immunity was detected in the majority of breeding ken-
nels. Rather, unexpected findings are the presence of non-
vaccinated adult dogs, especially when kept in breeding
kennels: the vaccine against this infection is indeed part of
the core vaccinations [12]. Current guidelines recommend
parvovirus revaccination of adult dogs no more frequently
than every 3 years, which is considered the minimum dur-
ation of immunity [7]. Our findings confirm that the anti-
body titre is similar in the first 3 years following
vaccination, but in the following years, it still remains well
above the cut-off in a large number of dogs, although the
percentage of unprotected animals rises above 10% in the
last two time categories (37 < x < 48; > 49).
The habit of yearly vaccination is still rather diffuse in
the area of our investigation: for the majority of dogs, even
when we excluded those younger than 1 year, less than 12
months had indeed elapsed since the last vaccination.
When dogs recover from natural infection/disease due
to CPV-2, they develop lifelong immunity [6]. After ini-
tial MLV vaccination, the longest period of time that
antibody was found to persist was 10 years for dogs kept
in natural environments [6]. Additionally, in our dog
population, there was one case of protective antibody
titre 10 years after the last vaccination, and further, the
case of a 14-year-old English Setter female that was still
protected 13 years after the first and only vaccination.
Notwithstanding single cases, at the population level, in-
tervals of more than 4 years since the last vaccination
were determined to be the main risk factors for the ab-
sence of CPV-2 antibodies [13].
Immunity following vaccination can vary among dogs,
and our data confirm that older animals can show a decline
in immunity, called “immunosenescence”, which may make
them more susceptible to infectious diseases [6].
Due to the variable duration of immunity, current
guidelines give the option to test the animals for seroposi-
tivity before blind revaccination [7]; rapid and simple sero-
logical test kits are available for in-practice use and can
detect the presence of protective antibodies specific for ca-
nine distemper virus, canine adenovirus and CPV-2. The
main limit to the regular use of the kits is their cost, which
is equivalent to the cost of vaccination [12, 14].
Serological tests could be a useful tool to assess the ef-
fectiveness of vaccination in breeding kennels to check for
unprotected animals and identify the reasons for vaccin-
ation failure. Among the dogs included in our study, some
young animals did not show a protective serum antibody
titre notwithstanding recent vaccination. For two dogs of
different breeds and kept in the same breeding kennel, the
more likely hypothesis is an improperly preserved/admin-
istered vaccine. Detection of this condition would be es-
sential for a breeder to be able to correct inappropriate
practices that could have dangerous effects. Dogs that fail
to develop measurable antibody levels following adequate
parvovirus vaccinations may be ‘genetic non-responders’
and represent another cause of vaccination failure: it is es-
timated that up to one in 1000 dogs may be genetic non-
Fig. 3 Comparison of the time elapsed since last vaccination
between males and females showing lower than cut-off antibody
titres (P = 0.0509)
Fig. 4 Comparison of the time elapsed since last vaccination
between unprotected (lower than 1:100 titre) and protected
animals. (* = P < 0.05)
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responders to CPV-2 [12]. The four-year-old German
Shepherd that was revaccinated annually and had an anti-
body titre lower than the cut-off 2 months after the last
vaccination is likely to be a genetic non-responder. The
prevalence of one in 366 dogs, which is higher than what
was reported [12], could be referred to as the genetic re-
latedness of the animals that represent the population of
our investigation.
We did not record the type of the vaccine used for each
dog, but we confirmed that it was a modified live virus vac-
cine from any of the major international manufacturers. In
recent years, some concerns have arisen about the complete
efficacy of CPV-2-based vaccines against the antigenic vari-
ants that have quickly and completely replaced the original
type [3]. Vaccination of dogs with canine parvovirus type
2b would cross-protect against CPV-2a and CPV-2c, as well
as against CPV-2 [15]. In the animals immunized with
CPV-2, a substantial difference was found in the amount of
serum-neutralizing activity towards the antigenic variants
-2a, −2b, and -2c, which was lower than that towards the
original type [1]. However, dogs that show a strong active
immune response, demonstrated by very high antibody ti-
tres following repeated immunizations, are likely to be pro-
tected against the disease regardless of the variant [1].
Conclusions
Our data show that the serological titre within 3 years
since the last vaccination is generally far higher than the
minimum protective titre. Serological tests could be used
to monitor vaccination effectiveness in breeding kennels.
Methods
Animals
The study was carried out in 33 breeding kennels homo-
geneously distributed in the Piedmont region territory,
North-West Italy, in 2018. The kennels were of small/
medium size and housed a number of bitches of repro-
ductive age, ranging from 3 to 15, that produced a num-
ber of litters ranging from 2 to 10 per year. The kennel
history did not report episodes of parvovirus infection in
the last 5 years. In a single kennel, a bitch and one of her
puppies had died of parvovirus infection 3 years earlier.
The dog population consisted of 370 animals, 257 fe-
males and 113 males. The mean age (±standard devi-
ation) of the bitches and the dogs was (4.3 ± 2.9) and
(4.8 ± 3.0), respectively, ranging from 8months to 16
years for females and 11months to 13 years for males.
All dogs were healthy and under veterinary control. The
minimum age of inclusion in the study was 8months, and
40–60% of the selectable animals were sampled in each ken-
nel. The mean number of dogs tested in each breeding ken-
nel was 7.8 (±6.5) females and 3.4 (±3.3) males, ranging
from a minimum of 0 to a maximum of 15 males and from
a minimum of 1 and a maximum of 25 females. Only breeds
with an average weight higher than 8 kg were chosen to
make blood collection easier and less stressful for the dogs.
The represented breeds and the relative numbers are the fol-
lowing: Afghan hound (11), Airedale Terrier (5), Alpenlaen-
discheDachsbracke (7), Akita Inu (17), American
Staffordshire terrier (7), AppenzellerSennenhund (13),
Australian Shepherd (52), Bernese Mountain Dog (20),
Bloodhound (3), Border Collie (7), Boxer (3), Clumber Span-
iel (2), Czechoslovakian Wolfdog (3), Deutsch Kurzhaar (7),
English Setter (33), French Bulldog (7), German Shepherd
(36), Golden Retriever (36), HannoverscherSchweisshund
(2), BraccoItaliano (2), Miniature American Shepherd (2),
Pointer (3), Poodle (3), Riesenschnauzer (4), Romagna
Water Dog (7), Rottweiler (15), Saarloos Wolfhound (4),
Scotch Collie (6), SegugioMaremmano (1), Siberian Husky
(2), ShibaInu (10), SpinoneItaliano (7), Staffordshire Bull ter-
rier (14), Vizsla (5), Zwergpinscher (4), Weimaraner (3),
White Swiss Shepherd Dog (5), and Whippet (2).
For each animal, sex, age and time of the last vaccin-
ation against parvovirus were recorded.
The study was carried out in accordance with the guide-
lines for the care and use of animals of the Department of
Veterinary Sciences of the University of Turin (Italy) and
with the consent of the dog owners.
Sample collection
Blood samples (2ml) were collected by cephalic
venipuncture into 8ml blood collection tubes (Vacuette®, Z
Serum Sep Clot Activator, Greiner Bio-One North America
Inc., North Carolina, USA) and carried to the laboratory at
4 °C within 5 h of collection.
Serum was separated by centrifugation (3500 rpm/min
for 10 min) and stored frozen at − 20 °C until assayed.
Antibody analysis
Determination of antibodies to CPV-2 in serum samples
was carried out with a commercial kit (Parvo Ab ELISA,
AGROLABO, Scarmagno, TO, Italy) consisting of an in-
direct immunoenzymatic assay with spectrophotometric
reading (450 nm), which had been validated by the manu-
facturer in relation to the ‘gold standard’ haemagglutin-
ation inhibition test with a declared sensitivity of 95% and
specificity of 98.5%. The sample optical density/positive
control optical density (S/P) ratio was calculated. Accord-
ing to the suggested cut-off, sera with S/P values lower
than 0.15 were detected as CPV-2 negative, while samples
with S/P values higher than 0.15 were classified as CPV-2
positive. The S/P value was used, according to the manu-
facturer’s instructions, for the calculation of antibody ti-
tres using the following formula: Antibody titres =
54(e^4(S/P)). A value of 1:100 was considered the minimum
protective titre by the manufacturer.
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Statistical analysis
All data were analysed using GraphPad Prism (vers. 6;
GraphPad Software, California, USA). The normality of dis-
tribution was tested using Kolmogorov and Smirnov tests.
The number of months that had elapsed since the last
vaccination was calculated for each animal.
The correlation between months from vaccination and
antibody titre was calculated by means of Spearman’s
test. An arbitrary value of 25,000 was attributed to out-
of-scale antibody titres.
The time elapsed since the last vaccination was catego-
rized in the following classes: < 12months; 13–24months;
25–36months; 37–48months; and > 49months. Antibody
titres for each class were compared using the Kruskal-
Wallis test, followed by Dunn’s post-tests.
The Mann-Whitney test was applied to compare the
time from vaccination in animals showing values higher
or lower than the cut-off antibody titre and between males
and females.
Values of P < 0.05 were considered statistically
significant.
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